The European Medicines Agency (EMA) has published its list of applications for new human medicines that are under evaluation as of July 2026. The document, released on 14 July 2026, provides an overview of the medicines currently undergoing the centralised marketing authorisation procedure, which allows pharmaceutical companies to seek a single EU-wide approval. The list includes applications for new active substances, as well as extensions of indications for already authorised medicines. The publication is a routine monthly update that informs stakeholders about the pipeline of new therapies that may soon reach the European market. The EMA's evaluation process assesses the quality, safety, and efficacy of each medicine before granting a marketing authorisation valid in all EU member states. The July 2026 list covers applications submitted in previous months and now under active review by the Committee for Medicinal Products for Human Use (CHMP). The document does not disclose specific product names or therapeutic areas, but it serves as a transparency tool for industry, healthcare professionals, and patients. No prior coverage of this monthly update exists in the available record. The EMA typically publishes such lists at the beginning of each month, and the July edition follows the same format as previous months. The agency's centralised procedure is mandatory for certain types of medicines, including those for rare diseases, cancer, diabetes, and autoimmune disorders. The publication of the list is part of EMA's commitment to openness and to providing timely information on the regulatory status of new medicines. Stakeholders, including pharmaceutical companies and patient organisations, use the list to track the progress of applications and anticipate potential new treatment options. The EMA's CHMP meets monthly to adopt opinions on marketing authorisation applications, and the July list reflects the current workload of the committee. The agency does not provide a timeline for when decisions on these applications will be reached, as review times vary depending on the complexity of each medicine. The July 2026 list is available on the EMA's website and will be updated as the evaluation process advances.
Source📄 Open document ↗